Novel Anti-gd-iga1 nanobody and use thereof

Novel nanobodies targeting GD-IgA1 address the limitations of current IgA nephritis treatments by specifically binding to GD-IgA1, inhibiting immune complex formation, and facilitating non-invasive diagnosis and treatment of IgA nephritis.

WO2026235462A1PCT designated stage Publication Date: 2026-11-12UI (UNIVERSITY IND FOUNDATION) YONSEI UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/096577
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-04
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for IgA nephritis, particularly those targeting galactose-deficient IgA1 (GD-IgA1), are non-specific and carry significant side effects, lacking agents that can effectively inhibit or eliminate immune complexes formed by GD-IgA1, which are a major cause of kidney damage.

Method used

Development of novel nanobodies that specifically bind to GD-IgA1 with high affinity, inhibiting immune complex formation and providing therapeutic and diagnostic compositions for IgA1 nephritis.

Benefits of technology

The nanobodies effectively block GD-IgA1 deposition, offering superior tissue penetration and binding capabilities, enabling non-invasive diagnosis and targeted treatment of IgA nephritis, potentially delaying disease progression and reducing side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026096577_12112026_PF_FP_ABST
    Figure KR2026096577_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides: an antibody or antigen-binding fragment thereof that specifically binds to a galactose-deficient IgA1 (Gd-IgA1) protein with high binding affinity; and a composition for diagnosing, preventing and treating Gd-IgA1-related diseases, using a newly discovered nucleic acid molecule encoding same. The present invention has great technical significance in newly establishing a non-invasive composition for diagnosing IgA1 nephritis, departing from conventional IgA1 nephritis diagnostic methods limited to invasive kidney biopsy. The nanobody of the present invention is a novel nanobody exhibiting a binding affinity improved by at least two-fold compared to existing anti-Gd-IgA1 antibodies, and is expected to establish new standards in the treatment and diagnosis markets for IgA1 glomerulonephritis.
Need to check novelty before this filing date? Find Prior Art

Description

Novel anti-GD-IGA1 nanobodies and their uses

[0001] The present invention relates to a novel nanobody that specifically binds to Gd-IgA1 (Galactose-deficient IgA1) protein and a composition for treating IgA1 nephritis using the same.

[0002]

[0003] Glomerulonephritis is a disease characterized by inflammation of the glomeruli in the kidneys. It is a serious condition that causes a decline in kidney function and can progress to chronic renal failure and end-stage renal disease (ESRD) in the long term. In particular, immunoglobulin A nephropathy (hereinafter IgA nephropathy) is the most common form of primary glomerulonephritis worldwide, and the production of galactose-deficient immunoglobulin A1 (GD-IgA1) and the deposition of complexes formed by the binding of autoantibodies to it in the glomeruli are known to be major causes of the disease. These immune complexes deposit in the glomeruli, induce an inflammatory response, and cause a decline in kidney function by inducing glomerular damage and fibrosis.

[0004] Conventional treatments for IgA nephritis include antihypertensive drugs, steroids, and immunosuppressants; however, most of these treatments are non-specific, carry risks of various side effects, and are merely symptomatic therapies focused on alleviating symptoms. In particular, therapeutic agents that directly target GD-IgA1, known as the underlying cause of IgA nephritis, have been developed only to a limited extent so far. Accordingly, there is an urgent need for the development of new drugs that can specifically bind to GD-IgA1 to inhibit or eliminate the formation of immune complexes.

[0005] GD-IgA1 is characterized by a galactose deficiency in the O-linked glycosylation structure located at the hinge site of the IgA1 molecule, and no therapeutic agent targeting this abnormal structure has yet been clinically approved. Accordingly, antibody-based therapeutic agents capable of specifically binding to GD-IgA1 are expected to prevent or delay disease progression by selectively inhibiting or eliminating immune complex formation, which is a major pathogenesis of IgA nephritis.

[0006] Meanwhile, nanobodies are single-domain antibodies derived from antibodies of camelid animals (e.g., llamas, alpacas). Compared to conventional IgG antibodies, they are smaller in size, have higher thermal stability, and possess excellent tissue penetration capabilities. Due to these characteristics, they offer superior in vivo distribution and drug delivery efficiency compared to traditional monoclonal antibodies, and also possess various advantages in terms of production processes. Furthermore, nanobodies can be utilized in various forms, such as drug carriers, diagnostic molecules, or therapeutic antibodies. In particular, since nanobodies exist with exposed antigen-binding sites, they have the advantage of being able to bind to epitopes that are difficult for traditional antibodies to access.

[0007] Therefore, nanobodies that specifically bind to GD-IgA1 can penetrate deep into kidney tissue thanks to their small size and high stability, and by binding with high affinity to the Gd-IgA1 protein, which is the cause of IgA1 nephritis, they can overcome the limitations of conventional treatments that are merely symptomatic treatments.

[0008]

[0009] Throughout this specification, numerous papers and patent documents are referenced and cited. The disclosures of the cited papers and patent documents are incorporated by reference into this specification in their entirety to more clearly explain the state of the art to which the present invention pertains and the content of the present invention.

[0010]

[0011] The inventors made diligent research efforts to develop a new nanobody capable of specifically binding to GD-IgA1 in order to effectively inhibit the glomerular deposition of immune complexes formed by the binding of GD-IgA1 (Galactose-deficient IgA1) and autoantibodies to it. As a result, they discovered a novel anti-Gd-IgA1 nanobody capable of recognizing GD-IgA1 with high affinity and binding to it, and completed the present invention by clearly elucidating the structure of their antigen recognition site.

[0012] Accordingly, the object of the present invention is to provide an antibody that specifically binds to the Gd-IgA1 protein or an antigen-binding fragment thereof.

[0013] Another objective of the present invention is to provide an antibody that specifically binds to the Gd-IgA1 protein or a nucleic acid molecule encoding an antigen-binding fragment thereof.

[0014] Another objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of Gd-IgA1-related diseases comprising, as an active ingredient, an antibody or an antigen-binding fragment thereof that specifically binds to a Gd-IgA1 protein; or a nucleic acid molecule encoding the same.

[0015] Another objective of the present invention is to provide a composition for diagnosing Gd-IgA1-related diseases comprising, as an active ingredient, an antibody that specifically binds to the Gd-IgA1 protein or an antigen-binding fragment thereof.

[0016]

[0017] Other objects and advantages of the present invention are more clearly explained by the following detailed description of the invention, claims, and drawings.

[0018]

[0019] According to one aspect of the present invention, the present invention provides an antibody or an antigen-binding fragment thereof that specifically binds to a Gd-IgA1 protein, comprising a CDR3 region having an amino acid sequence selected from the group consisting of sequences 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, and 59.

[0020] The inventors made diligent research efforts to discover an anti-GD-IgA1 antibody capable of blocking the formation of immune complexes and effectively inhibiting glomerular deposition by specifically binding to Gd-IgA1 (Galactose-deficient-IgA1), which is the main cause of IgA1 nephritis. As a result, the present invention was completed by first identifying that a nanobody containing a CDR (Complementary Determining Region) of a specific amino acid sequence can bind to the Gd-IgA1 protein with high affinity.

[0021] Sequences 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, and 59 of the sequence list of the present invention are each CDR3 sequences of F2 monomer, 30S monomer, 54S monomer, 101H monomer, 104Q monomer, SS monomer, 30SQ monomer, 54SH monomer, 54SQ monomer, HQ monomer, SSH monomer, SSQ monomer, 30SHQ monomer, 54SHQ monomer, and SSHQ monomer, which are candidates for antigen-binding fragments of antibodies discovered in the present invention, specifically nanobodies.

[0022]

[0023] As used herein, the term “IgA1 protein” refers to an immunoglobulin molecule containing an α1 heavy chain among human immunoglobulin A isosomes. Specifically, it includes IgA1 having an O-linked glycosylation site in the hinge region. The IgA1 protein includes all forms such as monomer, dimer, polymer, or secretory IgA1, and may also include recombinant proteins, naturally derived proteins, or functional variants thereof.

[0024] As used herein, the term “GD-IgA1 protein” refers to galactose-deficient IgA1 in which O-linked glycans in the hinge region are not sufficiently bound to galactose. Specifically, the GD-IgA1 protein refers to an IgA1 protein comprising O-glycans in a form in which galactose is not sufficiently bound to N-acetylgalactosamine, and includes both a partially galactose-deficient form and a substantially galactose-deficient form.

[0025]

[0026] As used herein, the term “antibody” refers to a peptide that recognizes a specific epitope of the Gd-IgA1 protein and binds specifically to it, and includes not only the complete antibody form but also the antigen-binding fragment (antibody fragment) of the full-length antibody molecule. A complete antibody has a structure comprising two full-length light chains and two full-length heavy chains, with each light chain connected to the heavy chain by a disulfide bond. The heavy chain constant region has gamma (γ), mu (μ), alpha (α), delta (δ), and epsilon (ε) types, and has subclasses gamma 1 (γ1), gamma 2 (γ2), gamma 3 (γ3), gamma 4 (γ4), alpha 1 (α1), and alpha 2 (α2). The light chain constant region has kappa (κ) and lambda (λ) types.

[0027] As used herein, the term “antigen-binding fragment of an antibody” refers to a fragment having a significant antigen-antibody binding function within a full-length antibody molecule, and includes Fab, F(ab'), F(ab')2, Fv, and nanobodies (nanobody or sybody), etc. Specifically, the antigen-binding fragment is a nanobody.

[0028] Fab, among the antibody fragments, has a structure having a variable region of the light chain and heavy chain, a constant region of the light chain and a first constant region (CH1) of the heavy chain, and has one antigen binding site.

[0029] Fab' differs from Fab in that it has a hinge region containing one or more cysteine ​​residues at the C-terminus of the heavy chain CH1 domain. F(ab')2 antibodies are produced when the cysteine ​​residues in the hinge region of Fab' form disulfide bonds. Fv is a minimal antibody fragment containing only a heavy chain variable region and a light chain variable region; in two-chain Fv, the heavy chain variable region and the light chain variable region are connected by non-covalent bonds, while in single-chain Fv, the heavy chain variable region and the single chain variable region are generally connected by covalent bonds via a peptide linker or directly at the C-terminus, allowing them to form a dimer-like structure similar to that of two-chain Fv.

[0030] As used in this specification, the term “nanobody” refers to a single-domain antibody analog composed of only one heavy chain variable region, and has the same meaning as “single-domain antibody (VHH antibody)” or “synthetic nanobody (sybody)” and may be used interchangeably. A nanobody is the smallest fully functional antigen-binding fragment. Typically, a single-domain antibody (Variable Domain of Heavy-chain Antibodies, VHH) composed of only one heavy chain variable region can be constructed by first obtaining an antibody that naturally lacks a light chain and a heavy chain constant region 1 (CH1), and then cloning the variable region of the antibody heavy chain. Nanobodies can be manufactured by artificially processing antibody fragments extracted from camelid animals such as camels, llamas, and alpacas. They have the advantages of being one-tenth the size of a normal antibody, being resistant to external environments such as temperature changes, being easy to administer, and having a high production yield.

[0031] As used in this specification, the term “heavy chain” means both the full-length heavy chain and fragments thereof, comprising an amino acid sequence having a sufficient variable region sequence to confer specificity to an antigen, a variable region domain VH, and three constant region domains CH1, CH2 and CH3.

[0032] As used herein, the term “CDR (complementarity determining region)” refers to the amino acid sequence of a hypervariable region of an immunoglobulin heavy chain and a light chain. The heavy chains (HCDR1, HCDR2, and HCDR3) and light chains (LCDR1, LCDR2, and LCDR3) each contain three CDRs, and these CDRs provide major contact residues for the antibody to bind to an antigen or epitope.

[0033] The range of the antibody or antigen-binding fragment of the present invention includes variants having conservative amino acid substitutions in the CDR region. Additionally, the antibody or antigen-binding fragment of the present invention may include variants of the amino acid sequences described in the attached sequence list within a range capable of specifically recognizing the Gd-IgA1 protein. For example, additional changes may be made to the amino acid sequence of the antibody to further improve the binding affinity and / or other biological properties of the antibody. Such modifications include, for example, deletion, insertion, and / or substitution of amino acid sequence residues of the antibody and are based on the relative similarity of amino acid side chain substituents, e.g., hydrophobicity, hydrophilicity, charge, size, etc. Analysis of the size, shape, and type of amino acid side chain substituents reveals that arginine, lysine, and histidine are all positively charged residues; alanine, glycine, and serine have similar sizes; and phenylalanine, tryptophan, and tyrosine have similar shapes. Based on these considerations, arginine, lysine, and histidine; alanine, glycine, and serine; and phenylalanine, tryptophan, and tyrosine can be considered biologically functional equivalents.

[0034] Furthermore, amino acid substitutions in proteins that do not alter the overall activity of the molecule are known in the art (H. Neurath et al., The Proteins, Academic Press, New York, 1979). The most common exchanges are those between amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thr / Phe, Ala / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, and Asp / Gly.

[0035] Considering the variant having the aforementioned biologically equivalent activity, the amino acid sequence constituting the antibody of the present invention is interpreted to include a sequence that exhibits substantial identity with the sequence listed in the sequence list. The above substantial identity refers to a sequence that exhibits at least 61% homology, 70% homology according to one specific example, 80% homology according to another specific example, and 90% homology according to yet another specific example when the sequence of the present invention is aligned to correspond as much as possible with any other sequence and the aligned sequence is analyzed using an algorithm commonly used in the art. Alignment methods and algorithms for sequence comparison are disclosed in Huang et al. Comp. Appl. BioSci. (1992) 8:155-65 and Pearson et al. Meth. Mol. Biol. (1994) 24:307-31, etc.

[0036] As used herein, the term "specifically binds" means that an antibody or its antigen-binding fragment, such as a structure like a nanobody, forms a relatively stable complex with an antigen under physiological conditions. Specific binding is approximately 1 x 10⁻⁶ -6 It can be specified by an equilibrium dissociation constant (KD value) of M or less. Methods for determining whether two molecules specifically bind are well known in the art, such as equilibrium dialysis and surface plasmon resonance.

[0037] As used herein, the term “affinity” refers to the sum of the strengths of all non-covalent interactions between a single binding site of a molecule (e.g., antibody) and its binding partner (e.g., antigen). Unless otherwise specified, “binding affinity” refers to the intrinsic binding affinity reflecting the one-to-one interaction between members of a binding pair (e.g., antibody and antigen). The affinity of molecule X for its partner Y can generally be expressed as a dissociation constant (KD). Affinity can be measured by conventional methods known in the art, including the method described in the present invention.

[0038]

[0039] According to a specific embodiment of the present invention, the antibody or its antigen-binding fragment additionally comprises a CDR1 region having an amino acid sequence selected from the group consisting of sequences 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, and 57.

[0040] Sequences 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, and 57 of the sequence list of the present invention are each CDR1 sequences of F2 monomer, 30S monomer, 54S monomer, 101H monomer, 104Q monomer, SS monomer, 30SQ monomer, 54SH monomer, 54SQ monomer, HQ monomer, SSH monomer, SSQ monomer, 30SHQ monomer, 54SHQ monomer, and SSHQ monomer, which are candidates for antigen-binding fragments of antibodies discovered in the present invention, specifically nanobodies.

[0041]

[0042] According to a specific embodiment of the present invention, the antibody or its antigen-binding fragment additionally comprises a CDR2 region having an amino acid sequence selected from the group consisting of sequences 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, and 58.

[0043] Sequences 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, and 58 of the sequence list of the present invention are each CDR2 sequences of antigen-binding fragments of antibodies discovered in the present invention, specifically nanobody candidates F2 monomer, 30S monomer, 54S monomer, 101H monomer, 104Q monomer, SS monomer, 30SQ monomer, 54SH monomer, 54SQ monomer, HQ monomer, SSH monomer, SSQ monomer, 30SHQ monomer, 54SHQ monomer, and SSHQ monomer.

[0044]

[0045] According to a more specific embodiment of the present invention, the antibody or its antigen-binding fragment of the present invention provides one or more antibodies or their antigen-binding fragments selected from the group consisting of (a) to (o):

[0046] (a) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 1 of sequence list, CDR2 having the amino acid sequence of sequence 2 of sequence list, and CDR3 having the amino acid sequence of sequence 3 of sequence list;

[0047] (b) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 5 of the sequence list, CDR2 having the amino acid sequence of sequence 6 of the sequence list, and CDR3 having the amino acid sequence of sequence 7 of the sequence list;

[0048] (c) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 9 of the sequence list, CDR2 having the amino acid sequence of sequence 10 of the sequence list, and CDR3 having the amino acid sequence of sequence 11 of the sequence list;

[0049] (d) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 13 of the sequence list, CDR2 having the amino acid sequence of sequence 14 of the sequence list, and CDR3 having the amino acid sequence of sequence 15 of the sequence list;

[0050] (e) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 17 of the sequence list, CDR2 having the amino acid sequence of sequence 18 of the sequence list, and CDR3 having the amino acid sequence of sequence 19 of the sequence list;

[0051] (f) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 21 of sequence list, CDR2 having the amino acid sequence of sequence 22 of sequence list, and CDR3 having the amino acid sequence of sequence 23 of sequence list;

[0052] (g) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 25 of the sequence list, CDR2 having the amino acid sequence of sequence 26 of the sequence list, and CDR3 having the amino acid sequence of sequence 27 of the sequence list;

[0053] (h) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 29 of the sequence list, CDR2 having the amino acid sequence of sequence 30 of the sequence list, and CDR3 having the amino acid sequence of sequence 31 of the sequence list;

[0054] (i) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 33 of the sequence list, CDR2 having the amino acid sequence of sequence 34 of the sequence list, and CDR3 having the amino acid sequence of sequence 35 of the sequence list;

[0055] (j) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 37 of the sequence list, CDR2 having the amino acid sequence of sequence 38 of the sequence list, and CDR3 having the amino acid sequence of sequence 39 of the sequence list;

[0056] (k) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 41 of the sequence list, CDR2 having the amino acid sequence of sequence 42 of the sequence list, and CDR3 having the amino acid sequence of sequence 43 of the sequence list;

[0057] (l) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 45 of the sequence list, CDR2 having the amino acid sequence of sequence 46 of the sequence list, and CDR3 having the amino acid sequence of sequence 47 of the sequence list;

[0058] (m) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 49 of the sequence list, CDR2 having the amino acid sequence of sequence 50 of the sequence list, and CDR3 having the amino acid sequence of sequence 51 of the sequence list;

[0059] (n) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 53 of the sequence list, CDR2 having the amino acid sequence of sequence 54 of the sequence list, and CDR3 having the amino acid sequence of sequence 55 of the sequence list;

[0060] (o) An antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 57 of the sequence list, CDR2 having the amino acid sequence of sequence 58 of the sequence list, and CDR3 having the amino acid sequence of sequence 59 of the sequence list.

[0061]

[0062] According to the most specific embodiment of the present invention, the antibody or its antigen-binding fragment comprises an amino acid sequence selected from the group consisting of sequence 4, sequence 8, sequence 12, sequence 16, sequence 20, sequence 24, sequence 28, sequence 32, sequence 36, sequence 40, sequence 44, sequence 48, sequence 52, sequence 56, and sequence 60.

[0063] According to the present invention, sequences 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, and 60 are each full-length amino acid sequences of an antigen-binding fragment of an antibody provided by the present invention, specifically a nanobody.

[0064]

[0065] According to a specific embodiment of the present invention, the antibody or its antigen-binding fragment is a monomer, a heterodimer, or a homodimer.

[0066] More specifically, the heterodimer may be a dimer in which the antibody or its antigen-binding fragment selected from the group consisting of (a) to (n) is combined with the dimer (o).

[0067] More specifically, the homodimer may be an antibody composed of (o) or an antigen-binding fragment thereof.

[0068] The inventors discovered F2 nanobodies with significantly improved binding affinity through three rounds of nanobody screening. Furthermore, using in silico-based antibody optimization tools, they identified more than 15 nanobodies with dramatically improved binding affinity by substituting some amino acids constituting the F2 nanobody monomers with other amino acids.

[0069] Among the above nanobodies, the SSHQ monomer of SEQ ID No. 60, in which a total of four amino acids—two serines (S), one histidine (H), and one glutamine (Q)—constituted the F2 monomer, showed the best binding affinity performance. Based on this discovery, optimal dimer sequences were discovered by combining the SSHQ monomer with other monomers using a linker.

[0070] In this specification, the term “linker” refers to a molecule that connects two spatially separated identical or different substances via covalent bonds as a bifunctional ligand compound having two reactive functional groups at both ends, and low molecular weight compound linkers or peptide linkers may be used without limitation. More specifically, the linker used in the present invention is a peptide linker. In this specification, the term “peptide linker” refers to a synthetic amino acid sequence that connects two polypeptide domains by forming peptide bonds with each of the N-terminus and C-terminus. For example, the peptide linker may linearly connect a first domain and a second domain, each having independent biological activity. More specifically, the peptide linker is composed of 3 to 12 amino acid residues, and even more specifically, is composed of 3 to 9 amino acid residues.

[0071] In addition, the peptide linker used in the present invention is an aaa linker or a flexible peptide linker composed of glycine and serine. The flexible peptide linker composed of glycine and serine includes all linkers in which glycine and serine residues are arranged in any order. Specifically, the flexible peptide linker composed of glycine and serine is a linker comprising a peptide of (GGGGS)n or (GGGS)n (where n is an integer from 1 to 3). More specifically, the linker is (GGGGS)1, (GGGS)1 is a linker containing a combination thereof, most specifically a GGGGSGGGS linker or a GGGSGGGGS linker.

[0072]

[0073] As shown in the examples described below, the binding affinity of the dimer sequences was measured using ELISA, and the result showed a superior Fold change (GD-IgA / IgA) value compared to the existing anti-Gd-IgA1 antibody KM55.

[0074] Accordingly, the present invention provides a heterodimer comprising an SSHQ monomer (o) having the CDR sequence of SEQ ID NOs. 57 to 59 and a monomer comprising any one antibody selected from the group consisting of (a) to (n) or an antigen-binding fragment thereof, and specifically, a heterodimer comprising (j) and (o) which is an antibody having the amino acid sequence of SEQ ID NOs. 37 to 39. The heterodimer has a fold change (GD-IgA / IgA) value 2.14 times higher than that of the existing anti-Gd-IgA antibody KM55, and has a significantly higher binding affinity compared to the existing anti-Gd-IgA antibody.

[0075] In addition, as described above, the present invention provides a homodimer in which an SSHQ monomer of (o) comprising the CDR sequences of SEQ ID NOs 57 to 59 is combined through the linker of the present invention described above.

[0076]

[0077] According to a specific embodiment of the present invention, the nanobody of the present invention is an antibody or an antigen-binding fragment thereof having an average molecular weight of 10 to 18 kDa.

[0078] The nanobody has an average molecular weight that is one-tenth the size of a normal antibody, so it has excellent tissue penetration ability. Specifically, the average molecular weight of the nanobody provided by the present invention is 11 to 17 kDa, more specifically 12 to 17 kDa, even more specifically 13 to 17 kDa, and most specifically 14 to 16 kDa.

[0079]

[0080] According to another aspect of the present invention, the present invention provides an antibody that specifically binds to a Gd-IgA1 (Galactose-deficient IgA1) protein or a nucleic acid molecule encoding an antigen-binding fragment thereof.

[0081] As for the antibodies and antigen-binding fragments used in the present invention, their description is omitted to prevent excessive duplication.

[0082] As used herein, the term “nucleic acid molecule” encompasses DNA (gDNA and cDNA) and RNA molecules, and nucleotides, which are the basic building blocks of nucleic acid molecules, include not only natural nucleotides but also analogues in which sugar or base sites are modified (Uhlman et al., Chemical Reviews (1990)90:543-584). The sequence of a nucleic acid molecule encoding a full-length antibody, an antigen-binding fragment, or a portion of the domains thereof according to the present invention may be modified, and said modification includes the addition, deletion, or non-conservative or conservative substitution of nucleotides.

[0083] The nucleic acid molecule of the present invention is interpreted to include a sequence that exhibits substantial identity with respect to the nucleotide sequence of the present invention. The above-mentioned substantial identity refers to a nucleotide sequence that exhibits at least 80% homology, at least 90% homology in one specific example, and at least 95% homology in another specific example when any other sequence is aligned to correspond as much as possible with the nucleotide sequence of the present invention described above and the aligned sequence is analyzed using an algorithm commonly used in the art.

[0084] Specifically, the nucleic acid molecule used in the present invention may be an mRNA molecule, and more specifically, may be an IVT (in vitro transcribed) mRNA.

[0085]

[0086] When mRNA is used as the nucleic acid molecule of the present invention, various modifications may be applied to improve the expression (translation) efficiency of the antibody or antigen-binding fragment of the present invention, such as, for example, a change in the poly(A) tail length or a substitution of some adenine bases; a modification of the 5' cap; or the application of one or more modified nucleosides. Specifically, the modified nucleosides that may be applied include, but are not limited to, N1-methylpseudouridine, pseudouridine, 2-thiouridine, 5-methyluridine, 5-methylcytidine, and 5-methoxyuridine, and any modified nucleoside known in the art may be applied.

[0087]

[0088] According to another aspect of the present invention, the present invention provides a pharmaceutical composition for the prevention or treatment of Gd-IgA1 (Galactose-deficient IgA1)-related diseases comprising, as an active ingredient, the antibody of the present invention or an antigen-binding fragment thereof; or a nucleic acid molecule encoding the same.

[0089] As for the antibodies, antigen-binding fragments, and nucleic acid molecules encoding the same used in the present invention, the description thereof is omitted to prevent excessive duplication.

[0090] In this specification, the term “Gd-IgA1 (Galactose-deficient IgA1) related disease” means a disease that occurs or progresses due to the production, accumulation, or immune response to galactose-deficient IgA1 (Gd-IgA1), and includes IgA nephropathy, Henoch-Schonlein purpura (IgA vasculitis), chronic kidney disease, IgA vasculitis, chronic liver disease, or a prodromal or complication stage of such diseases. However, it is not limited thereto and includes all diseases caused by the production or accumulation of Gd-IgA1 protein and all diseases caused by structural mutations of IgA1. Specifically, the Gd-IgA1 related disease may be a kidney-related disease, and more specifically, may be glomerulonephritis. Most specifically, the glomerulonephritis mentioned above may be IgA nephropathy.

[0091] As used herein, the term “prevention” means preventing the occurrence of a disease or illness in subjects who have not been diagnosed with having such a disease or illness but are at risk of developing such a disease or illness.

[0092] As used herein, the term “treatment” means (a) inhibition of the progression of a disease, illness, or symptom; (b) alleviation of a disease, illness, or symptom; or (c) elimination of a disease, illness, or symptom. When a composition of the present invention is administered to a subject, the antibody of the present invention specifically binds to Gd-IgA1 to neutralize the pathological action of the Gd-IgA1 antigen or to regulate the immune response, thereby inhibiting the progression of Gd-IgA1-related diseases, such as IgA nephritis, or alleviating or eliminating symptoms.

[0093] Accordingly, the composition of the present invention may serve as a composition for treating these diseases on its own, or it may be administered together with other pharmacological components to be applied as an adjuvant for the treatment of said diseases. Accordingly, in this specification, the terms “treatment” or “therapeutic agent” include the meanings of “adjuvant for treatment” or “adjuvant for treatment.”

[0094] As used herein, the terms “administration” or “to administer” refer to directly administering a therapeutically effective amount of the composition of the present invention to a subject so that an equal amount is formed within the subject’s body.

[0095] In the present invention, the term “therapeutic effective amount” refers to the content of a composition in which the pharmacological component within the composition is contained in an amount sufficient to provide a therapeutic or preventive effect to an individual to whom the pharmaceutical composition of the present invention is to be administered, and includes the meaning of “preventive effective amount.”

[0096] In this specification, the term “object” includes, without limitation, humans, mice, rats, guinea pigs, dogs, cats, horses, cattle, pigs, monkeys, chimpanzees, baboons, or rhesus monkeys. Specifically, the object of the present invention is a human.

[0097]

[0098] According to another aspect of the present invention, the present invention provides a composition for diagnosing Gd-IgA1 (Galactose-deficient IgA1)-related diseases comprising, as an active ingredient, the antibody of the present invention or an antigen-binding fragment thereof; or a nucleic acid molecule encoding the same.

[0099] As for the GD-IgA1-related disease, antibody, antigen-binding fragment, and nucleic acid molecule encoding the same used in the present invention, the description thereof is omitted to prevent excessive duplication.

[0100] Currently, the definitive diagnosis of IgA nephritis relies on invasive kidney biopsy; however, this method entails physical burden and risks of complications for the patient, and has limitations in that repeated testing is difficult. Accordingly, the inventors have discovered a diagnostic composition capable of non-invasively diagnosing IgA nephritis based on novel nanobodies that can specifically bind to Gd-IgA1. The diagnostic composition provides a diagnostic platform capable of replacing and complementing existing invasive diagnostic methods due to the small molecular size and excellent tissue penetration of the nanobodies.

[0101] Specifically, the present invention provides a probe capable of non-invasively diagnosing IgA nephritis by combining a nanobody that specifically binds to anti-Gd-IgA1 with imaging technologies such as PET / CT, thereby enabling early diagnosis and regular follow-up of IgA nephritis. The nanobody has a very small molecular size compared to traditional antibodies and possesses structural characteristics suitable for PET / CT probes, as it allows for easy tagging at the C-terminus, resulting in excellent labeling ease. Furthermore, by utilizing a PET / CT diagnostic agent based on a nanobody labeled with a radioisotope, the problems associated with conventional invasive diagnostic methods can be effectively resolved. Accordingly, the diagnostic composition for Gd-IgA1-related diseases provided by the present invention is labeled with a radioisotope and can be used for imaging diagnosis.

[0102] As used herein, the term “diagnosis” includes the determination of an individual’s susceptibility to a specific disease, the determination of whether an individual currently possesses a specific disease, and the determination of the prognosis of an individual afflicted with a specific disease.

[0103] In this specification, the term “diagnostic composition” refers to a concept comprising a mixture or equipment for diagnosing Gd-IgA1-related diseases or predicting diagnostic potential by measuring the presence or expression level of Gd-IgA1 protein, and may also be expressed as a “diagnostic kit.” The composition comprises the antibody of the present invention or an antigen-binding fragment thereof that specifically binds to Gd-IgA1, and can be used for detecting Gd-IgA1 in a sample.

[0104]

[0105] The features and advantages of the present invention are summarized as follows:

[0106] (a) The present invention provides a composition for the diagnosis, prevention, and treatment of Gd-IgA1-related diseases by providing an antibody or an antigen-binding fragment thereof that specifically binds to a Gd-IgA1 (Galactose-deficient IgA1) protein; and a nucleic acid molecule encoding the same.

[0107] (b) The novel anti-Gd-IgA1 nanobody discovered by the present invention binds to Gd-IgA1 with high binding affinity to effectively block the cause of IgA1 glomerulonephritis, and by disclosing a diagnostic composition that enables the diagnosis of IgA1 nephritis by a non-invasive method, it is expected to set a new standard in the diagnostic market for IgA1 glomerulonephritis.

[0108]

[0109] Figure 1 is a schematic diagram illustrating the characteristics of a nanobody, showing the high tissue penetration power and in vivo stability of a nanobody derived from an antibody of a camelid animal.

[0110] Figure 2 is a schematic diagram illustrating the pathogenesis of IgA nephropathy (IgAN), showing the process by which IgA nephropathy develops due to abnormally glycosylated Gd-IgA1.

[0111] Figure 3 is a diagram illustrating the structure of an antibody that specifically binds to IgA1, showing the existence of a hinge region where O-glycosylation occurs intensively.

[0112] Figure 4a is a schematic diagram illustrating a screening process for selecting nanobodies with excellent binding affinity, in which screening is performed through ribosome display in the first round and phage display in the second and third rounds, and ELISA (enzyme-linked immunosorbent assay) is performed on the selected candidates. Figure 4b is a diagram showing the process of analyzing intermolecular binding of the candidates selected through the process of Figure 4a using BLI (Bio-Layer Interferometry) technology.

[0113] Figure 5 is a diagram showing the qPCR results of the ribosome display (1st round), 1st phage display (2nd round), and 2nd phage display (3rd round) in the screening step of Figure 4a. Figure 5a shows the ribosome display of the 1st round, Figure 5b shows the 1st phage display of the 2nd round, and Figure 5c shows the 2nd phage display of the 3rd round.

[0114] Figure 6a is a figure showing the results of performing an ELISA on candidate groups selected through the first and second phage display processes of Figure 4a, and shows that phages were enriched after the second phage display. Figure 6b is a bar graph showing the quantitative analysis of the ELISA results of Figure 6a.

[0115] Figure 7 is a diagram quantitatively showing the BLI values ​​between the F2 nanobody monomers and dimers selected through the screening process of Figure 4a and the target peptide (Gd-IgA1 hinge peptide).

[0116] Figure 8 is a diagram showing the specific binding properties of the F2 monomer. Figure 8a is a diagram evaluating the non-specific binding potential of the nanobody using Enbrel, an antibody known to be rich in O-glycosylation, and shows the results through BLI analysis that it binds only to Gd-IgA1 and not to GD-Enbrel. Figure 8b is a bar graph showing the quantitative analysis of sandwich ELISA experimental results using Gd-IgA protein rather than a peptide. Figure 8c is a bar graph showing the results of a competition ELISA using HPA (Helix pomatia agglutinin) to confirm whether the F2 dimer actually binds to the hinge region of Gd-IgA1.

[0117] Figure 9a is a schematic diagram illustrating the affinity maturation process using in silico-based antibody optimization tools to improve the binding affinity of F2 nanobodies, and Figure 9b is a bar graph showing the results of ELISA performed on candidate variants (4 single amino acid variants) selected through the process of Figure 9a.

[0118] Figure 10a is a diagram showing the results of ELISA performed by creating monomer sequences with all 1 (single), 2 (double), 3 (triple), and 4 amino acids substituted, unlike Figure 9b (single amino acid variant), and Figure 10b is a diagram showing the results of the ELISA quantitatively analyzed and displayed as a bar graph.

[0119] Figure 11 is a figure showing the results of performing ELISA on a total of 16 dimers produced by immobilizing the SSHQ monomer that showed the best binding affinity in Figure 10b and binding it with 15 mutant monomers and 1 F2 monomer using an aaa linker.

[0120] FIG. 12 is a diagram showing the results of further analyzing the binding characteristics of the F2-based dimer nanobody candidates of the present invention.

[0121] Figure 13 is a diagram showing the results of BLI analysis for selecting candidates exhibiting excellent binding characteristics among F2-based dimer nanobody candidates.

[0122] Figure 14 is a diagram showing additional analysis results to verify the improvement in binding affinity of F2 nanobodies and their variants.

[0123] Figure 15 is a figure showing the results of comparing the binding affinity to Gd-IgA of variants with 1, 2, 3, or 4 amino acids substituted based on the F2 monomer using ELISA, and shows that the SSHQ monomer was selected as the starting sequence for subsequent dimer optimization.

[0124] Figure 16 is a figure showing the results of comparing the binding affinity to Gd-IgA and selectivity against normal IgA of SSHQ-based dimer nanobodies fabricated by immobilizing an SSHQ monomer at the N-terminus and connecting 15 mutant monomers and 1 F2 circular sequence to the C-terminus, respectively, using a 9GS linker, using ELISA.

[0125] Figure 17 is a figure showing the results of comparing the structural stability of the entire complex and hinge peptide region by performing 300 ns molecular dynamics (MD) simulations on F2-9GS-F2 and SSHQ-9GS-104Q.

[0126] Figure 18 is a figure showing the results of comparing the binding affinity and selectivity of F2-9GS-F2 and SSHQ-9GS-104Q for Gd-IgA using BLI analysis.

[0127] Figure 19 is a diagram showing the results of a competition ELISA to determine whether SSHQ-9GS-104Q binds to the hinge region of Gd-IgA1 and inhibits the binding of HPA and KM55 in a concentration-dependent manner.

[0128] Figure 20 is a diagram showing the results of a BLI-based C1q blocking assay to determine whether SSHQ-9GS-104Q inhibits the binding of complement component C1q to the immune complex formed by Gd-IgA and autoantibodies.

[0129] Figure 21 is a diagram showing the results of a cell-based analysis to confirm that the pathological accumulation of Gd-IgA1 contributes to the early pathogenesis of IgA nephropathy.

[0130] Figure 22 is a diagram showing the results of confocal microscopy analysis and quantitative analysis of fluorescence intensity to confirm whether SSHQ-9GS-104Q inhibits the cell surface deposition of Gd-IgA in HMC.

[0131] Figure 23 is a diagram showing the results of a qPCR analysis to determine whether the increase in gene expression related to inflammation and fibrosis induced by Gd-IgA1 in HMC is suppressed by SSHQ-9GS-104Q.

[0132]

[0133] The present invention will be described in more detail below through examples. These examples are intended solely to explain the invention more specifically, and it will be obvious to those skilled in the art that the scope of the invention is not limited by these examples according to the gist of the invention.

[0134]

[0135] Examples

[0136] amino acid sequence of each nanobody

[0137] (1) F2 nanobody

[0138] 1) CDR1 (Sequence No. 1): GSISSITYLG

[0139] 2) CDR2 (Sequence No. 2): ALSTSSGTTY

[0140] 3) CDR3 (Sequence No. 3): ADHGLQYPLWNNAYWY

[0141] 4) Full length sequence (Sequence number 4)

[0142] :QVQLVESGGGSVQAGGSLLRLSCAASGSISSITY

[0143] LGWFRQAPGKEREGVAALSTSSGTTYYADSVKG

[0144] RFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAA

[0145] DHGLQYPLWNNAYWYWGQGTQVTVS

[0146] (2) 30S nanobody

[0147] 1) CDR1 (Sequence No. 5): GSISWITYLG

[0148] 2) CDR2 (Sequence No. 6): ALSTSSGTTY

[0149] 3) CDR3 (Sequence No. 7): ADHGLQYPLWNNAYWY

[0150] 4) Full length sequence (Sequence No. 8):

[0151] QVQLVESGGGSVQAGGSLLRLSCAASGSISWITY

[0152] LGWFRQAPGKEREGVAALSTSSGTTYYADSVKG

[0153] RFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAA

[0154] DHGLQYPLWNNAYWYWGQGTQVTVS

[0155] (3) 54S nanobody

[0156] 1) CDR1 (Sequence No. 9): GSISSITYLG

[0157] 2) CDR2 (Sequence No. 10): ALSTYSGTTY

[0158] 3) CDR3 (Sequence No. 11): ADHGLQYPLWNNAYWY

[0159] 4) Full length sequence (Sequence No. 12):

[0160] QVQLVESGGGSVQAGGSLLRLSCAASGSISSITY

[0161] LGWFRQAPGKEREGVAALSTYSGTTYYADSVKGR

[0162] FTVSLDNAKNTVYLQMNSLKPEDTALYYCAAA

[0163] DHGLQYPLWNNAYWYWGQGTQVTVS

[0164] (4) 101H nanobody

[0165] 1) CDR1 (Sequence No. 13): GSISSITYLG

[0166] 2) CDR2 (Sequence No. 14): ALSTSSGTTY

[0167] 3) CDR3 (Sequence No. 15): ADYGLQYPLWNNAYWY

[0168] 4) Full length sequence (Sequence No. 16):

[0169] QVQLVESGGGSVQAGGSLLRLSCAASGSISSITY

[0170] LGWFRQAPGKEREGVAALSTSSGTTYYADSVKGR

[0171] FTVSLDNAKNTVYLQMNSLKPEDTALYYCAAA

[0172] DYGLQYPLWNNAYWYWGQGTQVTVS

[0173] (5) 104Q nanobody

[0174] 1) CDR1 (Sequence No. 17): GSISSITYLG

[0175] 2) CDR2 (Sequence No. 18): ALSTSSGTTY

[0176] 3) CDR3 (Sequence No. 19): ADHGLWYPLWNNAYWY

[0177] 4) Full length sequence (Sequence No. 20):

[0178] QVQLVESGGGSVQAGGSLLRLSCAASGSISSITY

[0179] LGWFRQAPGKEREGVAALSTSSGTTYYADSVKG

[0180] RFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAA

[0181] DHGLWYPLWNNAYWYWGQGTQVTVS

[0182] (6) SS nanobody

[0183] 1) CDR1 (Sequence No. 21): GSISWITYLG

[0184] 2) CDR2 (Sequence No. 22): ALSTYSGTTY

[0185] 3) CDR3 (Sequence No. 23): ADHGLQYPLWNNAYWY

[0186] 4) Full length sequence (Sequence No. 24):

[0187] QVQLVESGGGSVQAGGSLLRLSCAASGSISWITY

[0188] LGWFRQAPGKEREGVAALSTYSGTTYYADSVKG

[0189] RFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAA

[0190] DHGLQYPLWNNAYWYWGQGTQVTVS

[0191] (7) 30SQ nanobody

[0192] 1) CDR1 (Sequence No. 25): GSISWITYLG

[0193] 2) CDR2 (Sequence No. 26): ALSTSSGTTY

[0194] 3) CDR3 (Sequence No. 27): ADHGLWYPLWNNAYWY

[0195] 4) Full length sequence (Sequence No. 28):

[0196] QVQLVESGGGSVQAGGSLLRLSCAASGSISWITY

[0197] LGWFRQAPGKEREGVAALSTSSGTTYYADSVKG

[0198] RFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAA

[0199] DHGLWYPLWNNAYWYWGQGTQVTVS

[0200] (8) 54SH nanobody

[0201] 1) CDR1 (Sequence No. 29): GSISSITYLG

[0202] 2) CDR2 (Sequence No. 30): ALSTYSGTTY

[0203] 3) CDR3 (Sequence No. 31): ADYGLQYPLWNNAYWY

[0204] 4) Full length sequence (Sequence No. 32):

[0205] QVQLVESGGGSVQAGGSLLRLSCAASGSISSITY

[0206] LGWFRQAPGKEREGVAALSTYSGTTYYADSVKG

[0207] RFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAA

[0208] DYGLQYPLWNNAYWYWGQGTQVTVS

[0209] (9) 54SQ nanobody

[0210] 1) CDR1 (Sequence No. 33): GSISSITYLG

[0211] 2) CDR2 (Sequence No. 34): ALSTYSGTTY

[0212] 3) CDR3 (Sequence No. 35): ADHGLWYPLWNNAYWY

[0213] 4) Full length sequence (Sequence No. 36):

[0214] QVQLVESGGGSVQAGGSLLRLSCAASGSISSITY

[0215] LGWFRQAPGKEREGVAALSTYSGTTYYADSVKG

[0216] RFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAA

[0217] DHGLWYPLWNNAYWYWGQGTQVTVS

[0218] (10) HQ Nanobody

[0219] 1) CDR1 (Sequence No. 37): GSISSITYLG

[0220] 2) CDR2 (Sequence No. 38): ALSTSSGTTY

[0221] 3) CDR3 (Sequence No. 39): ADYGLWYPLWNNAYWY

[0222] 4) Full length sequence (Sequence No. 40):

[0223] QVQLVESGGGSVQAGGSLLRLSCAASGSISSITY

[0224] LGWFRQAPGKEREGVAALSTSSGTTYYADSVKG

[0225] RFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAA

[0226] DYGLWYPLWNNAYWYWGQGTQVTVS

[0227] (11) SSH nanobody

[0228] 1) CDR1 (Sequence No. 41): GSISWITYLG

[0229] 2) CDR2 (Sequence No. 42): ALSTYSGTTYY

[0230] 3) CDR3 (Sequence No. 43): ADYGLQYPLWNNAYWY

[0231] 4) Full length sequence (Sequence No. 44):

[0232] QVQLVESGGGSVQAGGSLLRLSCAASGSISWITY

[0233] LGWFRQAPGKEREGVAALSTYSGTTYYADSVKG

[0234] RFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAA

[0235] DYGLQYPLWNNAYWYWGQGTQVTVS

[0236] (12) SSQ nanobody

[0237] 1) CDR1 (Sequence No. 45): GSISWITYLG

[0238] 2) CDR2 (Sequence No. 46): ALSTYSGTTY

[0239] 3) CDR3 (Sequence No. 47): ADHGLWYPLWNNAYWY

[0240] 4) Full length sequence (Sequence No. 48):

[0241] QVQLVESGGGSVQAGGSLLRLSCAASGSISWITY

[0242] LGWFRQAPGKEREGVAALSTYSGTTYYADSVKG

[0243] RFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAA

[0244] DHGLWYPLWNNAYWYWGQGTQVTVS

[0245] (13) 30SHQ Nanobody

[0246] 1) CDR1 (Sequence No. 49): GSISWITYLG

[0247] 2) CDR2 (Sequence No. 50): ALSTSSGTTY

[0248] 3) CDR3 (Sequence No. 51):ADYGLWYPLWNNAYWY

[0249] 4) Full length sequence (Sequence No. 52):

[0250] QVQLVESGGGSVQAGGSLLRLSCAASGSISWITY

[0251] LGWFRQAPGKEREGVAALSTSSGTTYYADSVKG

[0252] RFTVSLDNAKNTVYLQMNSLKPEDTALYYCAA

[0253] ADYGLWYPLWNNAYWYWGQGTQVTVS

[0254] (14) 54SHQ Nanobody

[0255] 1) CDR1 (Sequence No. 53): GSISSITYLG

[0256] 2) CDR2 (Sequence No. 54): ALSTYSGTTY

[0257] 3) CDR3 (Sequence No. 55): ADYGLWYPLWNNAYWY

[0258] 4) Full length sequence (Sequence No. 56):

[0259] QVQLVESGGGSVQAGGSLLRLSCAASGSISSITY

[0260] LGWFRQAPGKEREGVAALSTYSGTTYYADSVKG

[0261] RFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAA

[0262] DYGLWYPLWNNAYWYWGQGTQVTVS

[0263] (15) SSHQ Nanobody

[0264] 1) CDR1 (Sequence No. 57): GSISWITYLG

[0265] 2) CDR2 (Sequence No. 58): ALSTYSGTTY

[0266] 3) CDR3 (Sequence No. 59): ADYGLWYPLWNNAYWY

[0267] 4) Full length sequence (Sequence No. 60):

[0268] QVQLVESGGGSVQAGGSLLRLSCAASGSISWITY

[0269] LGWFRQAPGKEREGVAALSTYSGTTYYADSVKG

[0270] RFTVSLDNAKNTVYLQMNSLKPEDTALYYCAAAD

[0271] YGLWYPLWNNAYWYWGQGTQVTVS

[0272]

[0273] Experimental method

[0274] 1. Primer sequences used

[0275] The primer sequences used in the qPCR reaction of each step to synthesize the nanobody synthesized in the present invention are as follows.

[0276]

[0277] Sequence No. 61 (Long_FX_for): ATA TGC TCT TCT AGT CAA GTC CAG CTG GTG GAA TCG

[0278] Sequence No. 62 (Long_FX_rev): TAT AGC TCT TCA TGC AGA AAC GGT AAC TTG GGT GCC C

[0279] Sequence No. 63(qPCR_RD_5'_for): GGG AGA CCA CAA CGG TTT CCC

[0280] Sequence No. 64 (qPCR_RD_5'_rev): GCC GCT AGC CGC ACA GCT C

[0281] Sequence No. 65(qPCR-RD_tolA-3'_for): GCC GAA TTC GGA TCT GGT GGC

[0282] Sequence No. 66(qPCR_RD_tolA-3'_rev): CTG CTT CTT CCG CAG CTT TAG C

[0283] Sequence No. 67(qPCR_PD_pDX_for): GAC GTT CCG GAC TAC GGT TCC

[0284] Sequence No. 68 (qPCR_PD_pDX_rev): CAC AGA CAG CCC TCA TAG TTA GC

[0285]

[0286] 2. Biotinylation of Gd-IgA hinge peptide

[0287] EZ-Link Sulfo-NHS-SS-Biotin (Thermo Scientific, #A39258) was used to amine-specific biotinylate the Gd-IgA hinge peptide (Peptide Institute, #24017-s). Afterward, free biotin was removed using Slide-A-Lyzer MINI Dialysis Devices, 2K MWCO (Thermo Scientific, #69580).

[0288]

[0289] 3. Ribosome Display

[0290] PUREfrex2.1 (GeneFrontier, #PF213-0.25-EX), glutathione oxidase (GSSG), and disulfide-binding isomerase (DsbC) were mixed and reacted using a PCR cycler at 37°C for 5 minutes. Approximately 1.6 × 10⁻⁶ 12 0.7 μl of a nanobody RNA library containing mRNA strands was added, and the reaction was carried out at 37°C for an additional 30 minutes to form ribosome complexes. Subsequently, prior to the in vitro transcription of the ribosome complexes, 10 ml of each of the following solutions was prepared:

[0291] 1) WTB-BSA: 50mM Tris / acetate pH 7.4, 150mM NaCl, 50mM MgAc₂, 0.5% BSA

[0292] 2) WTB-D: 50mM Tris / acetate pH 7.4, 150mM NaCl, 50mM MgAc₂, 0.1% Tween20

[0293] 3) WTB-D-BSA: A solution obtained by adding 0.1% Tween20 to the above WTB-BSA.

[0294]

[0295] Subsequently, 12 μl of Dynabeads™ MyOne™ StreptavidinT1 beads (Invitrogen, 65601) were placed in an RNase-free / low-binding 1.5 ml tube and stored under ice-cold conditions. The beads were washed twice with WTB-BSA and then blocked in WTB-BSA for at least 20 minutes. Afterward, the ribosome complex was mixed with 100 μl of panning solution (WTB-D-BSA + 500 μg heparin + 1 μl RNaseIn) and centrifuged at 20,000×g for 5 minutes. The supernatant was collected and reacted with biotinylated Gd-IgA hinges under ice-cold conditions for 2 hours to form a ribosome-Gd-IgA complex.

[0296] The beads were washed three times with WTB-BSA, after which the complex mixture was added and reacted under ice-cold conditions for 1 hour to induce biotin-streptavidin binding. Subsequently, the entire mixture was washed three times with WTB-D, and the nanobody RNA was resuspended in RD elution buffer (50 mM Tris / acetate pH 7.4, 150 mM NaCl, 50 mM EDTA, yeast RNA 100 μg / ml) and reacted at room temperature for 20 minutes. Finally, the RNA was purified using the RNeasy kit (Qiagen, 74004) and finally eluted to 15 μl.

[0297]

[0298] 4. Reverse Warrior

[0299] A Gd-IgA hinge-specific nanobody cDNA library was constructed using RNA purified from ribosomal displays, and reverse transcription was performed in a 30 μl reaction according to the manufacturer's protocol using SuperiorScript III reverse transcriptase (Enzynomics, RT006M). The generated cDNA was purified using a PCR purification mini kit (Favorgen, FAGCK 001-1) and eluted to a final volume of 30 μl. Of the 30 μl, 2 μl was used for qPCR analysis, and the remaining 28 μl was used for subsequent amplification experiments.

[0300] Purified cDNA was amplified with Long_FX_For and Long_FX_Rev primers. The total PCR reaction volume was 100 μl, and the reaction was carried out by dividing into two tubes at the start.

[0301]

[0302] 5. qPCR analysis

[0303] qPCR analysis was used to monitor library enrichment during ribosome display and phage display selection, and to evaluate the quality of cDNA generated during the selection step. qPCR was performed using the AccuPower® 2 x Greenstar qPCR Master Mix (Bioneer, #K-6251) on a QuantStudio 3 real-time PCR instrument (Applied Biosystems).

[0304] The PCR reaction conditions were as follows: 2 min at 95°C (initial denaturation), 10 sec at 95°C; 30 sec at 57°C; 30 sec at 63°C (denaturation, annealing, extension, measurement) / the melting curve steps followed the default settings in the instrument manual.

[0305]

[0306] 6. Preparation of SS320 cells for electroporation

[0307] To transform the cDNA library of the ribosome display results, the SS320 strain was cultured overnight in TB medium with tetracycline (10 μg / ml).

[0308] Afterwards, 2 ml was inoculated into 200 ml of TB medium (antibiotic-free) in a 250 ml Erlenmeyer flask and incubated at 37°C at 160 rpm until OD600 = 0.4 was reached. Subsequently, the culture medium was cooled on ice for 10 minutes, and then centrifuged at 5,000×g for 10 minutes using a sterile bucket.

[0309] The supernatant was removed after centrifugation, and the cell pellet was resuspended in 40 ml of cold sterile 1 mM HEPES (pH 7.4), and this process was repeated twice. After the final centrifugation, the pellet was resuspended in 20 ml of cold sterile 10% ultrapure glycerol, centrifuged again for 10 minutes, and then the supernatant was removed. Finally, the pellet was resuspended in 300 μl of cold 10% glycerol, dispensed in 350 μl aliquots, rapidly frozen with liquid nitrogen, and stored at -80°C.

[0310]

[0311] 7. Electroporation

[0312] To utilize phage display, a concentrated nanobody library was inserted into the phagemid vector pDXinit. A frozen aliquot of SS320 cells was thawed on ice, and the ligation reaction mixture and electroporation cuvettes (0.2 cm apart) were prepared together on the ice. 50 μl of the ligation reaction mixture was gently pipetted into competent cells, and then pulsed using a BioRad Gen Pulser II system at 2.4 kV, 25 μF, and 300 Ω. Immediately after electroporation, the cells were transferred to 25 ml of SOC medium and cultured at 37°C at 160 rpm for 30 minutes. 25 μl of the recovered culture medium was serially diluted tenfold six times to create a total of seven dilution steps, and 125 μl of each step was plated onto LB agar plates containing 100 μg / ml ampicillin to verify the transformation efficiency. The remaining culture was inoculated into 225 ml of 2YT (ampicillin 100 μg / ml + glucose 2%) and incubated overnight at 37°C at 160 rpm.

[0313]

[0314] 8. Waste paper production

[0315] To prepare phages for phage display, 50 ml of 2YT medium (ampicillin 100 μg / ml, glucose 2%) was first prepared. 1 ml of overnight culture of electroporated cells was inoculated and cultured at 37°C and 160 rpm for about 2 hours until OD600 ≈ 0.6.

[0316] Subsequently, 30 μl of M13K07 helper phage (5×10¹² pfu / ml) was added to 10 ml of culture medium and incubated without shaking at 37°C for 30 minutes. After the reaction, the supernatant was removed by centrifugation at 5,000×g for 10 minutes, and the pellet was resuspended in 50 ml of 2YT medium (ampicillin 100 μg / ml + kanamycin 25 μg / ml). This was cultured overnight at 37°C and 160 rpm to produce phages.

[0317] The next day, the culture medium was centrifuged at 5,000×g for 30 minutes at 4°C, and 40 ml of the supernatant was transferred to a sterile tube. Then, 10 ml of PEG6000 / NaCl solution was added and the mixture was gently inverted to mix. This mixture was reacted on ice for 2 hours to precipitate the phages, and then centrifuged at 10,000×g for 1 hour to remove the supernatant, and the phage pellet was resuspended in 300 μl of PBS.

[0318] This was transferred to a 1.5 ml tube and centrifuged at 20,000×g for 5 minutes to remove aggregates, and this process was repeated twice. Finally, absorbances at 269 nm and 320 nm were measured using a UV-Vis spectrometer, and phage concentrations were calculated using the following formula:

[0319] Phages / ml=((A269-A320)×6×10 16 ) / 4900.

[0320]

[0321] 9. Grip Display

[0322] Before starting the phage display, 10 μg / ml of tetracycline was added to 5 ml of 2YT medium for the seed culture of the E. coli SS320 strain, and the mixture was incubated overnight with shaking at 37°C. Simultaneously, 100 μl of nutravidin (67 nM) was coated into 48 wells of a 96-well plate and reacted overnight at 4°C.

[0323] The next day, cells for infection were prepared by inoculating 1 ml of seed culture cultured overnight into 50 ml of new 2YT medium (containing 10 μg / ml tetracycline). The following buffers were prepared to initiate the primary phage display.

[0324] 1) TBS 50ml

[0325] 2) TBS-BSA (TBS + 0.5% BSA) 50ml

[0326] 3) TBS-BSA-D (TBS + 0.5% BSA + 0.1% Tween 20) 50ml

[0327] 4) TBS-D (TBS + 0.1% Tween 20) 150ml

[0328] The coated plates were washed once with 250 μl of TBS per well and then blocked with 250 μl of TBS-BSA at room temperature for 30 minutes. Subsequently, among the previously produced and purified phages, 5×10 12 PFU-containing phages were diluted in 5 ml of TBS-BSA-D and used, and 100 μl of this was transferred to a 1.5 ml tube and used as a negative control.

[0329] Biotinylated Gd-IgA hinge peptide was added to the remaining phage solution to a final concentration of 50 nM and mixed thoroughly, while biotinylated MBP was added to the negative control at a concentration of 50 nM. The two mixtures were reacted at room temperature for 2 hours to induce the formation of a complex between Gd-IgA and the phage. After washing the blocked plates once with 250 μl of TBS-BSA-D, the Gd-IgA hinge-phage mixture was dispensed into 47 wells, and the MBP control was dispensed into the remaining 1 well. Subsequently, the mixture was reacted at room temperature for 1 hour to form a nutravidin-Gd-IgA hinge peptide-phage complex.

[0330] All wells were washed three times with 250 μl of TBS-D and dried on a paper towel for 2 minutes between washes. Then, 100 μl of PD elution buffer (TBS + 0.25 mg / ml trypsin) was added to each well and reacted at room temperature for 10 minutes to elute the bound phages.

[0331] AEBSF solution was added to inhibit the action of trypsin. 2 μl of this was used for qPCR analysis to evaluate the output phage concentration relative to the input. The remaining eluent was added to 45 ml of pre-cultured SS320 cells and inoculated without shaking at 37°C for 30 minutes. The cells were then transferred to 200 ml of 2YT medium containing 100 μg / ml ampicillin and 2% glucose, and incubated overnight at 37°C at 160 rpm.

[0332] For the secondary display, 5×10 of the grippers amplified in the primary display 12 200 μl of phage solution containing PFU was prepared. Additionally, 10 ml each of TBS-BSA, TBS-BSA-D, and TBS-D were prepared, 12 μl of Dynabeads™ MyOne™ Streptavidin C1 (Invitrogen, 65001) was placed in a 1.5 ml tube, washed twice with 500 μl of TBS-BSA, and then blocked with 500 μl of TBS-BSA for at least 20 minutes.

[0333] To prepare the panning solution, 50 nM of biotinylated Gd-IgA hinge peptide was added to 100 μl of phage solution and mixed, and a negative control was prepared by adding biotinylated MBP at a concentration of 50 nM to the remaining phage solution. The two mixtures were reacted at room temperature for 2 hours to form phage-antigen complexes, and after washing the beads three times with TBS-BSA-D, they were resuspended in each panning solution and reacted for 1 hour to induce Gd-IgA-phage binding. Afterward, they were washed once with TBS-BSA-D.

[0334] For competitive selection, 100 μl of competition buffer containing 5 μM of non-biotinylated Gd-IgA was added to each tube and incubated for 3 minutes. After washing twice with TBS-D, 100 μl of PD elution buffer was added to elute the bound phages. After incubating at room temperature for 10 minutes, trypsin was inactivated by adding AEBSF; 2 μl of this was used for qPCR analysis, and the remainder was used to infect 1 ml of SS320 cells, placed in 2YT (ampicillin 100 μg / ml + glucose 2%) medium, and incubated overnight at 37°C and 160 rpm to amplify the phages.

[0335]

[0336] 10. ELISA

[0337] The nanobody library concentrated through two-stage phage display was cloned into the pSBinit vector (Addgene, #110100), transformed into E. coli BL21 by heat shock, and then cultured on LB agar plates containing 25 μg / ml chloramphenicol.

[0338] 1.2 ml of TB medium (added with 25 μg / ml chloramphenicol) was dispensed into each well of a 96-well deep-well plate (hereinafter referred to as "preculture plate"), and 95 cultured colonies were selected and inoculated into each well. The first well was set as a positive control, and the pSBinit strain expressing the MBP sybody Sb_MBP#1 (Addgene, #132699) was inoculated. The deep-well plates were sealed with gas-permeable film and incubated at 37°C at 300 rpm for 4 hours.

[0339] Subsequently, a second 96-well deep-well plate named "expression culture" was prepared, and 1 ml of pre-warmed TB medium (containing 25 μg / ml of chloramphenicol) was dispensed into each well. Then, 50 μl was taken from the preculture and transferred to the corresponding wells. This plate was incubated at 37°C and 300 rpm for 2 hours, and then incubated at 22°C and 300 rpm until the OD600 reached 0.4-0.8.

[0340] Once sufficient cell density was reached, L-(+)-arabinose at a final concentration of 0.02% was added to induce expression, and the cells were cultured overnight at 150 rpm at 22°C. The next day, cells were harvested by centrifugation at 5,000×g at 4°C for 15 minutes; the pellet obtained from the preculture was stored at -20°C for DNA purification, and the pellet obtained from the expression culture was resuspended in 100 μl of periplasmic extraction buffer (20% sucrose, 50 mM Tris pH 8.0, 0.5 mM EDTA, 0.5 μg / ml lysozyme in DW), vigorously vortexed, and incubated on ice for 30 minutes.

[0341] Subsequently, 900 μl of TBS + 1 mM MgCl₂ was added to each well, and the mixture was centrifuged again at 5,000 × g at 4°C for 15 minutes to obtain the supernatant. The periplasmic extract was used for ELISA analysis. To select nanobody clones that specifically bind to the Gd-IgA1 hinge peptide, 100 μl of nutravidin (67 nM) was coated onto a 96-well plate, sealed with an adhesive film, and reacted overnight at 4°C. The next day, each well was washed three times with 200 μl of TBS-D and then blocked with TBS-BSA for 30 minutes.

[0342] To compare the binding specificity between Gd-IgA1 hinge peptide and MBP, 100 μl of biotinylated Gd-IgA1 hinge peptide (50 nM) was added to one well and biotinylated MBP (50 nM) was added to another well, and the mixture was reacted for 20 minutes.

[0343] After the reaction, each well was washed three times with 200 μl of TBS-D, and 20 μl of periplasmic extract and 80 μl of TBS-BSA-D were added to each well to equalize the total volume. The mixture was then reacted for 20 minutes and washed three times again with TBS-D. Subsequently, 100 μl of anti-c-Myc mouse antibody (Invitrogen, MA1-980) diluted 1:1,000 was added and reacted for 20 minutes, and washed three times again with TBS-D.

[0344] Next, 100 μl of HRP-conjugated anti-mouse antibody (Invitrogen, 31430) diluted 1:10,000 was added and reacted for 20 minutes, followed by three final washes with TBS-D. Finally, 100 μl of TMB substrate was added to each well and reacted for 15 minutes until color appeared, after which the absorbance was measured at 650 nm at 5-minute intervals using a plate reader.

[0345]

[0346] 11. Nanobody Production and Purification

[0347] Nanobody clones considered positive candidates based on ELISA results were transformed into E. coli BL21 strain and cultured overnight at 37°C and 160 rpm. Of this, 2 ml was taken from 5 ml of the culture medium, inoculated into 200 ml of TB medium containing 25 μg / ml of chloramphenicol, and cultured at 37°C and 200 rpm until OD600 = 0.6 was reached.

[0348] After that, the culture temperature was lowered to 22°C and cultured for an additional hour at 150 rpm, then L-(+)-arabinose at a final concentration of 0.02% was added to induce expression, and cultured overnight at 37°C and 150 rpm.

[0349] The next day, the cells were harvested by centrifuging the culture medium at 5,000×g at 4°C for 15 minutes, and the pellet was resuspended in periplasmic extraction buffer (20 ml) on ice and incubated for 30 minutes. Afterwards, 180 ml of TBS containing 1 mM MgCl₂ was added and centrifuged again at 5,000×g at 4°C for 15 minutes.

[0350] The supernatant was divided into 50ml tubes, and for nanobody purification, 1ml of TALON® Superflow™ resin (Cytiva, #28957502) slurry was equilibrated with pH 8.0 TBS and reacted with the periplasmic extract at 4°C for 1 hour while gently rotating.

[0351] After binding was completed, the nanobody was washed three times with a washing buffer (50 mM Tris pH 8.0, 300 mM NaCl, 5 mM imidazole) and eluted using an elution buffer (50 mM Tris pH 8.0, 300 mM NaCl, 250 mM imidazole).

[0352] The final eluted nanobody was purified through a buffer exchange process using an Amicon® Ultra centrifugal concentration filter (3 kDa MWCO, Millipore, UFC900308).

[0353]

[0354] 12. Improvement of In-silico Affinity

[0355] To enhance the binding strength of the nanobody, the three-dimensional structures of the nanobody and the Gd-IgA hinge peptide were predicted using AlphaFold3. Since the Gd-IgA hinge site is glycosylated with GalNAc sugar, the structure of the corresponding sugar was generated using GLYCAM-Web and attached to the protein.

[0356] Subsequently, a total of 512 initial models were generated using Schrodinger's LigPrep, and the top 5 models were selected based on the Epikstate penalty and energy criteria. The selected protein structures were optimized using BioLuminate's Protein Preparation Wizard, and then PIPER Protein-Protein docking was performed to generate a total of 180 docking models that mimic the binding between the nanobody and the Gd-IgA hinge peptide.

[0357] Among these, 19 models with a PIPER docking score of -100 kcal / mol or less were selected, and for each model, the ΔΔG (change in binding affinity) was evaluated by applying BioLuminate's Residue Scanning function. Based on this evaluation, the top 100 mutations expected to improve affinity were extracted.

[0358] Finally, excluding structural frame residues, the potential for affinity enhancement was precisely analyzed by introducing mutations within a range where stability is maintained in a positive direction.

[0359]

[0360] 13. Bio-layer interferometry (BLI)

[0361] The binding affinity of nanobodies was measured using Bio-layer Interferometry (BLI) with Gator Bio's Gator Prime Instrument. Biotinylated antigens were immobilized on Small Molecule Analysis Probes (SMAPs), and all experiments were performed in black polypropylene 96-well microplates.

[0362] To prevent non-specific binding of the sensor, a reaction buffer containing 0.1% Tween-20 and 1% BSA was used, and the experiment consisted of a baseline setting for 60 seconds, antigen immobilization for 180 seconds, re-baseline for 120 seconds, association with the nanobody for 300 seconds, and dissociation for 300 seconds, and all processes were carried out at 400 rpm.

[0363] The obtained binding data was analyzed based on a 1:1 homogeneous ligand model, and binding kinetic parameters including the dissociation constant (KD) were calculated through steady-state analysis.

[0364]

[0365] 14. GD-IgA production using enzymes

[0366] Gd-IgA1 was enzymatically produced by treating human plasma-derived IgA1 (Sigma-Aldrich, 401098-1MG) with β-galactosidase (NEB, P0726S) and neuraminidase (Roche, 11080725001) in sodium acetate buffer (pH 5.0) at 37°C for 3 hours.

[0367] After the reaction, the solution was purified using Protein L agarose beads (Santa Cruz, sc-2336), and then the buffer was exchanged using an Amicon® Ultra centrifugal filter (100 kDa MWCO, Millipore, UFC910008).

[0368]

[0369] 15. Competitive ELISA

[0370] In the HPA competitive ELISA performed to evaluate the ability of anti-Gd-IgA1 hinge peptide nanobodies to block the Gd-IgA1 binding site, 100 μl of enzyme-treated Gd-IgA1 (50 nM) was first coated onto a 96-well plate, reacted overnight at 4°C, and then blocked with TBS-BSA for 30 minutes.

[0371] Subsequently, anti-Gd-IgA1 nanobodies of various concentrations were mixed with HPA lectin (0.1 μg / ml) and reacted at room temperature for 30 minutes. Then, 100 μl was dispensed into each well and reacted for another 1 hour. Afterward, the wells were washed three times with TBS-D, and 100 μl of HRP-conjugated streptavidin diluted 1:2,000 was added and reacted for 30 minutes. After washing three times again, 100 μl of TMB substrate was added to induce color development for 15 minutes, and the absorbance was measured at 450 nm.

[0372]

[0373] 16.In-silico peptide prediction

[0374] To generate the 3D structure of the Gd-IgA1 hinge peptide, an initial structural model of the IgA1 hinge peptide was first predicted using AlphaFold3. Subsequently, a 3D structural model of the Gd-IgA1 hinge peptide was constructed by attaching five GalNAc residues to the predicted model using GLYCAM-Web. In addition, the structure of the nanobody was also predicted using AlphaFold3, and the predicted structure was further optimized using BioLuminate's Protein Preparation Wizard.

[0375] The sequences used in the above analysis are as follows.

[0376] IgA1 hinge peptide: VPSTPPTPSPSTPPTPSPS

[0377] Gd-IgA1 hinge peptide: VPSTPPTPSPSTPPTPSPS (including GalNAc)

[0378]

[0379] 17. Fabrication and Expression of Variant Nanobodies

[0380] Based on the results of in-silico affinity enhancement, nanobody variants containing selected mutants were constructed via overlap extension PCR. The amplified mutant fragments were cleaved with SpeI (Enzynomics, R011S) and SalI (Enzynomics, CR009S) restriction enzymes and cloned into the pCMV SPORT6 (Addgene, 66915) mammalian expression vector containing a C-terminal His tag. The sequences of all constructed plasmid constructs were verified by Sanger sequencing prior to transfection.

[0381] To further enhance binding strength, multimeric nanobody constructs in the form of dimers and tetramers were constructed. For this purpose, PCR was performed using the Type IIS restriction enzyme Esp3I (Enzynomics, R116S) to assemble the nanobody repeat sequences while maintaining their orientation, and the obtained PCR product and the restriction enzyme-treated vector were ligated using T4 DNA ligase (Enzynomics, M001S).

[0382] For protein expression, HEK293T cells were cultured in DMEM (10% FBS, 1% penicillin-streptomycin) medium at 37°C and 5% CO₂ to produce approximately 3×10 6 After reaching the cells, 15 μg of plasmid DNA was transiently transfected using polyethyleneimine (PEI, 1 mg / mL stock) at a DNA:PEI ratio of 1:3 (w / w). Fifteen hours after transfection, the medium was replaced with FreeStyle™ 293 Expression Medium (Gibco, 12338018), and 5 nM of sodium butyrate (Sigma-Aldrich, B5887) was added to enhance protein expression. After incubation for 4 days, the supernatant containing the secreted nanobodies was collected, filtered through a 0.45 μm filter, and purified under native conditions using cobalt-based TALON resin. The purification process was performed in the same manner as the TALON purification method described above.

[0383] 18.Alexa Fluor 647 labeling

[0384] Amine-directed labeling was performed using FSD Fluor™ 647 NHS ester (BioActs, KOSC1315) for the fluorescent labeling of Gd-IgA and IgA. Specifically, the dye was added in a molar excess of 20 times the protein weight, and the reaction was carried out at room temperature in the dark for 2 hours with gentle mixing. After the reaction, free dye was removed using Zeba Spin Desalting Columns (7K MWCO, 0.5 mL; Thermo Scientific, 89882), and the buffer was exchanged with PBS (pH 8.0). The labeled proteins were stored at 4°C in the dark.

[0385]

[0386] 19.MD simulation

[0387] After loading the selected docking model, protein preparation was performed in the SchrOdinger environment. Subsequently, the system was constructed using Desmond System Builder, and TIP3P water was applied as the solvent model. Gating parameters necessary for the simulation were set, and charge recalculation was performed to make the total charge zero. In addition, to simulate the physiological environment, ions were added, and an OPLS4 force field was applied to conduct MD simulations. The simulation was performed for a total of 500 ns, and 500 frames were extracted for analysis.

[0388]

[0389] 20. Functional assay

[0390] 20-1) KM55 blocking assay

[0391] A KM55 blocking assay was performed to evaluate whether the binding of the KM55 antibody is inhibited by anti-Gd-IgA1 nanobodies. First, 67 nM Neutravidin was coated onto a 96-well plate and incubated overnight at 4°C to form a capture surface. After blocking, biotinylated Gd-IgA1, prepared by enzymatic treatment of biotinylated human IgA (Rockland, 009-0606), was added to each well and immobilized by incubation at room temperature for 1 hour. Subsequently, to evaluate competitive inhibition, the anti-Gd-IgA1 nanobodies were serially diluted and pre-incubated with the KM55 antibody (IBL, 10777) at room temperature for 1 hour. The mixture was transferred to antigen-coated wells and incubated for 30 minutes, after which it was washed three times with TBS-T. Conjugated KM55 was detected for 30 minutes at room temperature using HRP-conjugated Goat anti-Rat IgG(H+L) (ThermoFisher Scientific, 31470), and finally developed for 15 minutes using a TMB substrate.

[0392]

[0393] 20-2) Hinge peptide deposition assay

[0394] To evaluate the deposition of biotinylated hinge peptide on the HMC surface, 1×10 5Cells were resuspended in 100 μL of PBS (0.5 μM or 1 μM) containing hinge peptide. The same conditions were applied to 293T cells as a negative control. After incubation at 4°C for 1 hour, the cells were labeled with Streptavidin-HRP conjugate (Thermo Fisher Scientific, N100) at 4°C for 30 minutes. After the reaction, 5,000 events were acquired using flow cytometry, and fluorescence intensity was quantified using FlowJo software.

[0395]

[0396] 20-3) Gd-IgA deposition assay on HMC

[0397] To evaluate the HMC deposition of Gd-IgA1, 1×10 5 Dog cells were prepared in 50 μL of PBS and stained using both direct and indirect methods, respectively. For the direct method, cells were treated with 2 μM of Gd-IgA1 labeled with Alexa Fluor 647 and incubated at 4°C for 2 hours. For the indirect method, unlabeled Gd-IgA1 was treated under the same conditions, washed twice with PBS, and incubated with an anti-human IgA antibody (Biolegend, 411502) at 4°C for 1 hour. Subsequently, the cells were stained with the Goat anti-Mouse IgG(H+L) secondary antibody, Alexa Fluor™ 647 (Invitrogen, A-21235), at 4°C for 30 minutes.

[0398] After the final wash, 5,000 events were analyzed using flow cytometry, and fluorescence intensity was quantified using FlowJo software.

[0399]

[0400]

[0401] 20-4) Confocal microscopy analysis

[0402] To visualize the intracellular deposition of Gd-IgA1, 3×10³ HMCs were treated with Alexa Fluor 647-labeled Gd-IgA1 or IgA1 (0.3 mg / mL) for 2 hours. After washing with PBS, fixation and permeabilization were performed using the BD Cytofix / Cytoperm™ Fixation / Permeabilization Kit (BD Biosciences, 554714). Subsequently, lysosomes were stained with LysoTracker™ Green DND-26 (Invitrogen, L7526), ​​and nuclei were stained with DAPI (1:5,000). After washing, the samples were mounted on slides using mounting media, covered with 12 mm coverslips, and images were acquired via confocal microscopy.

[0403] In addition, to evaluate lysosome damage after IgA treatment, HMCs were treated with Alexa Fluor 647-labeled Gd-IgA1 or Alexa Fluor 647-labeled IgA1 (control) at a concentration of 0.3 mg / mL at 37°C for 24 hours. Afterward, the samples were washed with PBS, and fixation / permeabilization was performed in the same manner, followed by blocking with 2% BSA in PBS at room temperature for 1 hour. After washing, the samples were co-stained with Anti-LAMP-1 antibody-Alexa Fluor 488 (5 μL / test; Sino Biological, 11215-R107-F) and Anti-Galectin-3 antibody-Alexa Fluor 594 (1:100; Santa Cruz Biotechnology, A3A12) at room temperature for 30 minutes. Subsequently, the samples were washed and analyzed by confocal microscopy.

[0404]

[0405] 20-5) qPCR Analysis

[0406] qPCR analysis was performed to quantify the mRNA expression of genes related to inflammation and fibrosis induced by Gd-IgA1 treatment. Specifically, HMCs were treated with Gd-IgA1 (0.2 mg / mL) or IgA1 (control, 0.2 mg / mL) at 37°C for 48 hours. To evaluate the inhibitory effect of the nanobody, Gd-IgA1 (0.2 mg / mL) and anti-Gd-IgA1 nanobody (0.2 mg / mL) were co-treated and incubated for 48 hours. Subsequently, total RNA was extracted using the AccuPrep® Universal RNA Extraction Kit (Bioneer, K-3141), and cDNA was synthesized using SuperiorScript III Reverse Transcriptase (Enzynomics, RT006L). qPCR was performed using AccuPower® 2X GreenStar™ qPCR Master Mix (Bioneer, K-6253). CD71, DPP1, MCP-1 (CCL2), Fibronectin (FN), and TNF-α were used as the genes for analysis, and 18S rRNA was used as the internal reference. Relative expression levels were calculated according to the 2^-ΔΔCt method.

[0407]

[0408] 20-6) C1q blocking assay

[0409] BLI was performed to evaluate whether C1q binds to the immune complex formed by Gd-IgA and KM55, and to confirm whether the SSHQ-9GS-104Q nanobody can block it. First, Gd-IgA (50 nM) was immobilized into a SMAB probe. Subsequently, KM55 (500 nM) and SSHQ-9GS-104Q nanobody were mixed at concentrations of 0.5 μM, 1 μM, and 2 μM, respectively, and the mixture was reacted with the immobilized Gd-IgA. Then, C1q (0.5 μM) was injected into the probe to measure changes in binding. The measurement protocol was carried out in the order of baseline (60 s) - loading (120 s) - baseline (60 s) - loading (120 s) - baseline (60 s) - association (600 s) - dissociation (600 s).

[0410]

[0411] 21. Statistical Analysis

[0412] Statistical analysis was performed using Prism v9 (GraphPad Software). Data were expressed as mean ± standard deviation (mean ± SD), as indicated in the figure legend. Statistical significance was evaluated using Student's multiple unpaired t-test, and the significance level was indicated as *p < 0.05.

[0413]

[0414] Experimental results

[0415] 1. Nanobody screening

[0416] Nanobody screening was conducted through a total of three rounds. Ribosome display was performed in the first round, while phage display was used in the second and third rounds to screen and select nanobodies. Fold change was evaluated using ELISA for the candidates obtained from each round, and a total of four candidates were selected. Subsequently, the intermolecular binding reactions of the selected candidates were quantitatively analyzed using bio-layer interferometry (BLI) analysis, which utilizes light interference, and KD values ​​were measured. As a result, among the four candidates selected by ELISA, only the single candidate F2 nanobody showed significant binding affinity in the BLI analysis, leading to the selection of F2 nanobody as the final candidate. Figure 4 is a schematic diagram illustrating the nanobody screening process described above, showing that F2 nanobody was discovered through the processes in Figures 4a and 4b. Figure 5 shows the qPCR values ​​for each screening step.

[0417] ELISA was performed using the phages selected after the first and second phage displays, which were the second and third rounds, and the OD600 value was measured. As a result, it was confirmed that the phages were concentrated after the second phage display (Fig. 6).

[0418] The binding affinity was measured by BLI analysis between the F2 nanobody monomer finally selected through the above process and the target peptide (Gd-IgA hinge peptide), and the BLI value was measured by fabricating the F2 nanobody monomer into a dimer form using a linker. In the case of the F2 nanobody monomer, the KD value for the target peptide was found to be approximately 459 nM, and in the case of the dimer form, it was confirmed that the KD value decreased to approximately 38 nM due to improved binding affinity (Fig. 7).

[0419]

[0420] 2. Determination of Specific Coupling

[0421] To determine the specific binding affinity of the nanobodies derived from the screening process, the potential for non-specific binding was evaluated using Enbrel, an antibody known to be rich in O-glycosylation. In this experiment, actual IgA protein was used instead of a peptide, and Gd-IgA1 was processed into a form with exposed GalNAc through treatment with β-galactosidase and neuraminidase. In the same manner, GD-Enbrel, an Enbrel with exposed GalNAc through β-galactosidase and neuraminidase treatment, was constructed, and binding affinity was evaluated using BLI analysis. As a result, it was confirmed that the F2 dimer showed binding only to Gd-IgA1 and did not bind to IgA, GD-Enbrel, or native Enbrel. Through the above experiment, it was confirmed that F2 nanobodies do not simply bind randomly to the exposed structure of GalNAc, but specifically react to the hinge region of Gd-IgA1 (Fig. 8a).

[0422] To verify whether the same specificity is maintained in formats other than BLI, a sandwich ELISA experiment using actual Gd-IgA protein instead of peptide was also conducted. KM55, a Gd-IgA1-specific antibody, was used as the positive control for this experiment. As a result, the F2 dimer exhibited a concentration-dependent binding signal to Gd-IgA1, whereas almost no binding signal was observed for normal IgA1. Through this, it was reconfirmed that the F2 dimer maintains specificity and binds not only to peptides but also to actual Gd-IgA1 protein (Fig. 8b).

[0423] Finally, to confirm whether the F2 dimer actually binds to the hinge region of Gd-IgA1, a competitive ELISA using HPA (Helix pomatia agglutinin) was performed. HPA is a lectin that specifically binds to GalNAc and has been widely used for detecting Gd-IgA1. In this experiment, Gd-IgA1 was treated simultaneously with the F2 dimer and HPA, and the signal was measured using streptavidin-HRP with biotin attached exclusively to HPA. Through this, the experiment was designed to determine whether the F2 dimer interferes with the binding of HPA by indirectly measuring the amount of HPA bound to Gd-IgA1. As a result, it was observed that the binding signal of HPA gradually decreased as the concentration of the F2 dimer increased, and it was confirmed that the F2 dimer effectively blocked the approach of HPA attempting to bind to GalNAc by binding to the hinge region of Gd-IgA1 and actually bound to the hinge region (Fig. 8c).

[0424]

[0425] 3. Insilico binding affinity enhancement (Affinity maturation)

[0426] Separate from the previously conducted ELISA and HPA blocking assays, in silico-based antibody optimization tools were used to enhance the binding affinity of F2 nanobodies. Specifically, AlphaFold3 and Glycam were utilized to predict and model the hinge peptide and corresponding O-glycosylation structure of Gd-IgA1. After selecting stable forms of the peptide and glycosylation structures using LigPrep in the Schrödinger program, docking simulations with F2 nanobodies monomers were performed based on these selections. Based on the models derived from the simulations, residue scanning analysis was conducted to predict amino acid variations that could contribute to improved binding affinity. As a result, 53 candidate variants were ultimately selected, each possessing a single point mutation in the CDR1, CDR2, and CDR3 regions.

[0427] Based on the results of the in silico analysis above, four single amino acid variants with excellent binding affinity were selected, and a pilot experiment was conducted. Specifically, variants were fabricated by inducing mutations in F2 nanobodies, and the binding affinity of each variant to the Gd-IgA1 hinge peptide was evaluated via ELISA. As a result, an improvement in binding signal was observed in all four variants, and in particular, the S30W variant in the CDR1 region showed the most prominent effect, exhibiting an increase in binding signal of approximately 30%. Figure 9a is a schematic diagram illustrating the affinity maturation process using the in silico-based antibody optimization tools mentioned above, and Figure 9b is a diagram showing the values ​​of binding affinity to the Gd-IgA1 hinge peptide measured via ELISA for the four selected single amino acid variants.

[0428] Furthermore, not limited to single point mutations, monomer sequences with two (double), three (triple), and four amino acids all substituted were prepared and ELISA was performed. As a result, the SSHQ monomer with four amino acids all substituted showed the strongest ELISA signal (Fig. 9b), and based on this, a dimer was constructed using an aaa linker. Fig. 10a is a diagram showing the results of performing ELISA on monomer sequences with amino acid substitutions, and Fig. 10b is a diagram showing the ELISA measurements quantitatively analyzed and represented as a bar graph.

[0429] In the previous experiment, the SSHQ monomer with the best binding affinity was immobilized, and ELISA was performed on a total of 16 dimers produced by conjugating 15 mutant monomers and 1 F2 monomer using an aaa linker. As a result, we were able to discover dimers with higher binding affinity than the previous F2-F2 dimers, and also those with higher fold change (GD-IgA / IgA) values ​​than the existing anti-Gd-IgA antibody KM55.

[0430] Figure 11 is a diagram showing the results of performing ELISA on a total of 16 dimers produced by immobilizing the SSHQ monomer and combining 15 mutant monomers and 1 F2 monomer using an aaa linker.

[0431]

[0432] 4. Further verification of recombinant nanobody screening results

[0433] To further verify the results of the nanobody screening described above, ELISA was performed at the recombinant nanobody level on the candidate group obtained through ribosome display and two rounds of phage display. Specifically, for a total of 95 candidate proteins, the binding signal to the Gd-IgA1 hinge peptide was compared as a fold change relative to the negative control, MBP. As a result, four candidate sequences (F2, F5, C7, and B11) exhibiting a binding signal 1.4 times greater than that of MBP could be selected. Based on these results, a candidate group exhibiting relatively superior binding affinity to the Gd-IgA1 hinge peptide was identified among the candidates obtained during the screening process, and these were selected for subsequent binding affinity evaluation (Fig. 12).

[0434]

[0435] 5. Further verification of the binding affinity of selected nanobodies

[0436] To further verify the binding affinity of the selected candidate nanobodies, BLI analysis was performed targeting the Gd-IgA1 hinge peptide. As a result, the monomer candidates F2 and C7 showed binding to the target peptide, but their binding affinity was relatively low. To improve avidity, F2-AAA-F2 and F2-AAA-C7 dimers were fabricated using a rigid tri-alanine (AAA) linker and compared, and F2-AAA-F2 exhibited the best binding characteristics. Furthermore, F2 homodimers incorporating a 9GS (GGGGGSGGGS) flexible linker were additionally fabricated and evaluated, and the results showed that the case using the flexible linker exhibited improved binding affinity compared to the case using the rigid linker. Specifically, the KD value of the F2 monomer was measured to be approximately 459 nM, the KD value of F2-AAA-F2 to be approximately 38 nM, and the KD value of F2-9GS-F2 to be approximately 9.7 nM. Thus, it was confirmed that the binding affinity of the F2 nanobody to the Gd-IgA1 hinge peptide can be significantly improved through dimerization, particularly through the introduction of a flexible linker (Fig. 13).

[0437]

[0438] 6. Further verification of the in silico-based binding affinity enhancement process

[0439] To further enhance the binding affinity of the above F2 nanobody, the in silico-based antibody optimization process itself was additionally validated. Specifically, the initial structures of the F2 nanobody and the IgA1 hinge peptide were predicted using AlphaFold3, and a Gd-IgA1 hinge peptide model reflecting the O-glycosylation structure of the hinge peptide was constructed using GLYCAM-WEB. Subsequently, multiple possible peptide conformations were generated using Schrodinger's LigPrep, and an antigen-nanobody complex model was constructed through PIPER docking. Afterward, residue scanning analysis was performed using BioLuminate to select mutations likely to contribute to improved binding affinity based on changes in binding free energy (ΔΔG). As a result, a total of 12,635 single-point mutation candidates were computationally generated, and among them, four single-amino acid mutation candidates with high potential for improved binding affinity were finally identified. The above results show that the nanobody optimization of the present invention is not a simple introduction of random mutations, but a rational optimization process based on structure-based design (Fig. 14).

[0440]

[0441] 7. Further verification of the binding strength of combinatorial variant monomer nanobodies

[0442] To further verify whether the four single amino acid variants selected through the above in silico analysis actually contribute to the improvement of binding affinity, ELISA was performed using multiple monomer nanobodies composed of combinations of these variants as well as single variants. Specifically, all-mutant constructs with one, two, three, and four amino acids substituted were constructed, and their binding signals to the Gd-IgA1 hinge peptide were compared. As a result, the SSHQ monomer containing all four mutations exhibited the highest ELISA binding signal compared to the parent sequence F2 and other combined variants. These results demonstrate that each single variant does not act independently, but rather that a synergistic improvement in binding strength can occur when multiple advantageous variants are combined. Therefore, it was confirmed that the SSHQ monomer is the optimal starting sequence for subsequent dimer optimization (Fig. 15).

[0443]

[0444] 8. Additional verification of the screening of SSHQ-based dimer nanobodies

[0445] Based on the excellent binding affinity of the aforementioned SSHQ monomer, SSHQ-based dimer nanobodies were fabricated to further enhance avidity, and their binding strength and specificity were verified. Specifically, SSHQ, which exhibited the best binding strength, was immobilized at the N-terminus, and 15 previously fabricated mutant monomers and one F2 circular sequence were attached to the C-terminus, respectively, to construct a total of 16 SSHQ-based dimers. The flexible linker 9GS was used as the linker. After expressing each construct, the binding strength to Gd-IgA and specificity relative to normal IgA were compared via ELISA; the results showed that SSHQ-9GS-104Q exhibited the best binding strength and selectivity. In other words, it was confirmed that the dimer with 104Q attached to SSHQ displayed improved binding characteristics compared to the wild-type based dimer. These results demonstrate that the affinity maturation results at the monomer level are maintained at the dimer level and can even be realized in an amplified form (Fig. 16).

[0446]

[0447] 9. Further verification of the structural stability of the finally selected dimer nanobodies

[0448] To further verify whether the enhanced binding strength of the finally selected SSHQ-9GS-104Q was structurally supported, 300 ns molecular dynamics (MD) simulations were performed on F2-9GS-F2 and SSHQ-9GS-104Q. As a result, F2-9GS-F2 exhibited a relatively unstable binding pattern with increasing RMSD variability in the hinge peptide region over time, whereas SSHQ-9GS-104Q maintained relatively constant RMSD values ​​in both the entire complex and the hinge peptide region, demonstrating a more stable binding state. Additionally, BLI analysis revealed that the KD value of SSHQ-9GS-104Q for Gd-IgA was approximately 393 nM, which was about three times higher than the KD value of F2-9GS-F2 for Gd-IgA, which was approximately 1.3 μM. Therefore, it was confirmed that the enhanced binding affinity of SSHQ-9GS-104Q is not due to simple experimental error, but is actually due to more stable antigen-nanobody interactions (Fig. 17).

[0449]

[0450] 10. Further verification of binding affinity and selectivity of the finally selected dimer nanobodies

[0451] To further verify the binding affinity and selectivity of SSHQ-9GS-104Q, the final selected among the above SSHQ-based dimer nanobodies, a BLI analysis targeting Gd-IgA was performed. Specifically, the binding reaction to Gd-IgA for SSHQ-9GS-104Q and the control group F2-9GS-F2 was quantitatively analyzed, and their respective KD values ​​were measured. As a result, F2-9GS-F2 showed a KD value of approximately 1.3 μM for Gd-IgA, whereas SSHQ-9GS-104Q showed a KD value of approximately 393 nM, demonstrating a binding affinity improved by about three times. In addition, it was confirmed that SSHQ-9GS-104Q exhibited superior selectivity for Gd-IgA. The above results reconfirm that the in silico-based optimization and dimerization strategy of the present invention is effective even at the actual Gd-IgA protein level, and show that SSHQ-9GS-104Q is suitable as a final treatment candidate (Fig. 18).

[0452]

[0453] 11. Further verification of the binding inhibitory effects of the finally selected nanobodies on HPA and KM55

[0454] To further verify whether the finally selected SSHQ-9GS-104Q actually binds to the hinge region of Gd-IgA1 and can interfere with the recognition of lectins and autoantibodies, a competitive ELISA using HPA and KM55 was performed. HPA is a lectin protein that binds to GalNAc exposed to the hinge, and KM55 is an antibody that recognizes the hinge region of Gd-IgA1 and is clinically used for the diagnosis of Gd-IgA1. In this experiment, Gd-IgA was treated with SSHQ-9GS-104Q along with HPA or KM55, and the residual binding signal was measured as the nanobody concentration increased. As a result, as the concentration of SSHQ-9GS-104Q increased, the binding signals of both HPA and KM55 decreased in a concentration-dependent manner. This means that SSHQ-9GS-104Q effectively binds to the hinge region of Gd-IgA1, blocking access by HPA, and also inhibits the binding of autoantibodies that recognize Gd-IgA1. Therefore, it was confirmed that the nanobody of the present invention has the potential to inhibit the formation of immune complexes between Gd-IgA1 and autoantibodies (Fig. 19).

[0455]

[0456] 12. Further verification of the C1q binding inhibitory effect of the finally selected nanobodies

[0457] To further verify whether the above-mentioned SSHQ-9GS-104Q can inhibit the binding of complement component C1q to immune complexes formed by Gd-IgA and autoantibodies, a BLI-based C1q blocking assay was performed. First, Gd-IgA was immobilized onto a probe, followed by the reaction with a sample mixed with KM55 and SSHQ-9GS-104Q, and then C1q was added to measure changes in binding. As a result, it was confirmed that the binding of C1q decreased as the concentration of SSHQ-9GS-104Q increased. This suggests that the nanobody of the present invention can inhibit complement activation through the classical pathway by inhibiting the interaction between Gd-IgA1 and autoantibodies. Therefore, it was confirmed that the nanobody of the present invention possesses a potential therapeutic effect capable of inhibiting downstream complement reactions following the formation of immune complexes, going beyond simple antigen binding blockage (Fig. 20).

[0458]

[0459] 13. Further verification of the deposition characteristics of Gd-IgA1 in human mesangium cells

[0460] To further verify whether Gd-IgA1 itself selectively binds to or deposits on human mesangial cells (HMCs), Gd-IgA1 and normal IgA1 were treated to HMCs, respectively, and then compared using confocal imaging. As a result, it was confirmed that Gd-IgA1 deposited more strongly on the surface of HMCs compared to normal IgA1. This implies that Gd-IgA1 can accumulate more effectively on mesangial cells on its own, even without necessarily forming immune complexes with autoantibodies. Furthermore, these results suggest that the abnormally exposed hinge region or glycosylated structure of Gd-IgA1 is involved in interactions with the surface of mesangial cells. Therefore, it was confirmed that the pathological accumulation of Gd-IgA1 itself may contribute to the early pathogenesis of IgA nephropathy (Fig. 21).

[0461]

[0462] 14. Further verification of the inhibitory effect of nanobodies on Gd-IgA1 deposition

[0463] To further verify whether the mesangial cell deposition of Gd-IgA1 described above can be inhibited by the nanobody of the present invention, confocal microscopy was performed after treating HMCs with Gd-IgA alone or together with SSHQ-9GS-104Q. As a result, Gd-IgA was distinctly deposited on the surface of HMCs, but when SSHQ-9GS-104Q was added, the cell surface deposition of Gd-IgA was significantly reduced. In addition, quantitative analysis of fluorescence intensity also confirmed that the deposition signal was significantly reduced in the nanobody-treated group. These results demonstrate that SSHQ-9GS-104Q can directly inhibit the cell surface attachment and accumulation of pathological Gd-IgA1 by masking the hinge region of Gd-IgA1. Therefore, it was confirmed that the nanobody of the present invention has an effect of inhibiting mesangial deposition, which is one of the key pathological conditions of IgA nephropathy (Fig. 22).

[0464]

[0465] 15. Further verification of the inhibitory effect of nanobodies on inflammation and fibrosis-related gene expression

[0466] To further verify whether the aforementioned inhibitory effect on Gd-IgA1 deposition leads to a reduction in actual intracellular inflammatory and fibrotic responses, HMCs were treated with Gd-IgA1 or normal IgA1 for 48 hours, and qPCR analysis was performed on a group treated with SSHQ-9GS-104Q along with Gd-IgA1. The genes used for analysis were CD71, DPP1, MCP-1 (CCL2), Fibronectin (FN), and TNF-α, and their relative expression levels were quantified using 18S rRNA as an internal reference. As a result, the expression of the aforementioned inflammation and fibrotic-related genes increased in the Gd-IgA1-treated group, whereas the expression of these genes was significantly reduced in the group treated with SSHQ-9GS-104Q. In particular, the increase in expression of CD71, MCP-1, TNF-α, and Fibronectin induced by Gd-IgA1 was effectively inhibited. Therefore, it was confirmed that the nanobody of the present invention can not only inhibit the deposition of Gd-IgA1 itself, but also alleviate the inflammatory activation and fibrotic response of mesangium cells associated therewith (Fig. 23).

[0467]

[0468] Foregoing, specific parts of the present invention have been described in detail. It is evident to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.

Claims

1. An antibody or antigen-binding fragment thereof that specifically binds to a Gd-IgA1 (Galactose-deficient IgA1) protein comprising a CDR3 region having an amino acid sequence selected from the group consisting of sequences 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, and 59.

2. The antibody or antigen-binding fragment of claim 1, wherein the antibody or the antigen-binding fragment thereof additionally comprises a CDR1 region having an amino acid sequence selected from the group consisting of sequences 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, and 57.

3. The antibody or antigen-binding fragment according to claim 1, wherein the antibody or the antigen-binding fragment thereof additionally comprises a CDR2 region having an amino acid sequence selected from the group consisting of sequences 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, 46, 50, 54, and 58 of the sequence list.

4. The antibody or its antigen-binding fragment according to claim 1, characterized in that the antibody or its antigen-binding fragment is one or more selected from the group consisting of (a) to (o) below: (a) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 1 of sequence list, CDR2 having the amino acid sequence of sequence 2 of sequence list, and CDR3 having the amino acid sequence of sequence 3 of sequence list; (b) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 5 of the sequence list, CDR2 having the amino acid sequence of sequence 6 of the sequence list, and CDR3 having the amino acid sequence of sequence 7 of the sequence list; (c) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 9 of the sequence list, CDR2 having the amino acid sequence of sequence 10 of the sequence list, and CDR3 having the amino acid sequence of sequence 11 of the sequence list; (d) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 13 of the sequence list, CDR2 having the amino acid sequence of sequence 14 of the sequence list, and CDR3 having the amino acid sequence of sequence 15 of the sequence list; (e) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 17 of the sequence list, CDR2 having the amino acid sequence of sequence 18 of the sequence list, and CDR3 having the amino acid sequence of sequence 19 of the sequence list; (f) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 21 of sequence list, CDR2 having the amino acid sequence of sequence 22 of sequence list, and CDR3 having the amino acid sequence of sequence 23 of sequence list; (g) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 25 of the sequence list, CDR2 having the amino acid sequence of sequence 26 of the sequence list, and CDR3 having the amino acid sequence of sequence 27 of the sequence list; (h) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 29 of the sequence list, CDR2 having the amino acid sequence of sequence 30 of the sequence list, and CDR3 having the amino acid sequence of sequence 31 of the sequence list; (i) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 33 of the sequence list, CDR2 having the amino acid sequence of sequence 34 of the sequence list, and CDR3 having the amino acid sequence of sequence 35 of the sequence list; (j) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 37 of the sequence list, CDR2 having the amino acid sequence of sequence 38 of the sequence list, and CDR3 having the amino acid sequence of sequence 39 of the sequence list; (k) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 41 of the sequence list, CDR2 having the amino acid sequence of sequence 42 of the sequence list, and CDR3 having the amino acid sequence of sequence 43 of the sequence list; (l) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 45 of the sequence list, CDR2 having the amino acid sequence of sequence 46 of the sequence list, and CDR3 having the amino acid sequence of sequence 47 of the sequence list; (m) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 49 of the sequence list, CDR2 having the amino acid sequence of sequence 50 of the sequence list, and CDR3 having the amino acid sequence of sequence 51 of the sequence list; (n) an antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 53 of the sequence list, CDR2 having the amino acid sequence of sequence 54 of the sequence list, and CDR3 having the amino acid sequence of sequence 55 of the sequence list; (o) An antibody or an antigen-binding fragment thereof comprising CDR1 having the amino acid sequence of sequence 57 of the sequence list, CDR2 having the amino acid sequence of sequence 58 of the sequence list, and CDR3 having the amino acid sequence of sequence 59 of the sequence list.

5. The antibody or its antigen-binding fragment according to claim 1, wherein the antibody or its antigen-binding fragment comprises an amino acid sequence selected from the group consisting of sequences 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, and 60.

6. The antibody or its antigen-binding fragment according to claim 4, characterized in that the antibody or its antigen-binding fragment is a monomer, a heterodimer, or a homodimer.

7. The above-mentioned heterodimer is an antibody or an antigen-binding fragment thereof characterized in that the above-mentioned (o) is bound to any one antibody or an antigen-binding fragment thereof selected from the group consisting of (a) to (n).

8. The antibody or antigen-binding fragment thereof characterized in that, in claim 6, the homodimer is composed of the above (o).

9. An antibody or an antigen-binding fragment thereof, characterized in that, in claim 1, the antigen-binding fragment is a nanobody.

10. An antibody or an antigen-binding fragment thereof, characterized in that, in claim 9, the nanobody has an average molecular weight of 10 to 18 kDa.

11. An antibody that specifically binds to the Gd-IgA1 (Galactose-deficient IgA1) protein of claim 1, or a nucleic acid molecule encoding an antigen-binding fragment thereof.

12. A pharmaceutical composition for the prevention or treatment of Gd-IgA1 (Galactose-deficient IgA1)-related diseases comprising, as an active ingredient, the antibody of claim 1 or an antigen-binding fragment thereof; or a nucleic acid molecule encoding the same.

13. A composition according to claim 12, characterized in that the Gd-IgA1 (Galactose-deficient IgA1) related disease is IgA1 nephritis.

14. A composition for diagnosing Gd-IgA1 (Galactose-deficient IgA1)-related diseases comprising, as an active ingredient, the antibody of claim 1 or an antigen-binding fragment thereof; or a nucleic acid molecule encoding the same.

15. A composition according to claim 14, characterized in that the Gd-IgA1 (Galactose-deficient IgA1) related disease is IgA1 nephritis.